Kevin D Lustig, Age 61433 Glencrest Dr, Solana Beach, CA 92075

6555326, Apr 29, 2003

Nov 21, 1997

08/975614

Kevin Lustig - South San Francisco CA
Patrick Baeuerle - South San Francisco CA
Holger Beckmann - South San Francisco CA
Jin-Long Chen - South San Francisco CA
Bei Shan - South San Francisco CA

Tularik Inc. - South San Francisco CA

G01N 3352

435 78, 435 71

Methods for identifying modulators of nuclear hormone receptor function comprise the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the receptor. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a recited nuclear hormone transcriptional coactivator motif sequence, the sensor is present at sub-micromolar concentration, the binding reaction occurs in solution, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label. Reagents include labeled sensor peptides and reaction mixtures consisting essentially of nuclear hormone receptor, a peptide and a candidate agent.

7101681, Sep 5, 2006

Sep 30, 1998

09/163713

Kevin Lustig - South San Francisco CA, US
Patrick Baeuerle - Gauting, DE
Holger Beckmann - South San Francisco CA, US
Jin-Long Chen - South San Francisco CA, US
Bei Shan - South San Francisco CA, US

Amgen, Inc. - Thousand Oaks CA

G01N 33/53

435 78, 434 71, 434 72

Methods for identifying modulators of nuclear hormone receptor function comprise the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the receptor. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a recited nuclear hormone transcriptional coactivator motif sequence, the sensor is present at sub-micromolar concentration, the binding reaction occurs in solution, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label. Reagents include labeled sensor peptides and reaction mixtures consisting essentially of nuclear hormone receptor, a peptide and a candidate agent.

2009009, Apr 16, 2009

Oct 3, 2008

12/245589

Kevin D. Lustig - Solana Beach CA, US
Andrew Martin - Woodside CA, US
Christopher L. Petersen - San Diego CA, US

The Assay Depot, Inc. - San Diego CA

G06Q 50/00
G06Q 30/00

705 2, 705 26

Disclosed herein are methods of facilitating transactions between clients and life science research service providers.

6316503, Nov 13, 2001

Mar 14, 2000

9/525861

Leping Li - Burlingame CA
Julio C. Medina - San Carlos CA
Kevin Lustig - South San Francisco CA
Bei Shan - Redwood City CA
Hirohiko Hasegawa - Osaka, JP
Serena T. Cutler - Palo Alto CA
Jiwen Liu - Burlingame CA
Liusheng Zhu - Burlingame CA

Tularik Inc. - So. San Francisco CA

A01N 4106

514604

The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The compounds and compositions find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.